Cargando…
The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
The AGILE trial compared ivosidenib and azacitidine versus azacitidine for IDH1-mutant acute myeloid leukemia (AML) in elderly patients who were ineligible to receive intensive chemotherapy. While the results of this trial appear encouraging, various concerns become evident from the study design and...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460510/ https://www.ncbi.nlm.nih.gov/pubmed/36063621 http://dx.doi.org/10.1016/j.tranon.2022.101523 |